ClinicalTrials.gg
TerminatedNCT02439957Updated Jul 16, 2021Results posted

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

A Phase 3 interventional study of Brincidofovir and Valganciclovir in Cytomegalovirus Disease and Kidney Transplant Infection, sponsored by Chimerix. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-16.

Sponsored by Chimerix (part of Jazz Pharmaceuticals) · Phase 3, Interventional, and Prevention

Why this study was terminated
Study terminated early due to results from another CMX001 study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing valganciclovir in Cytomegalovirus Infections — 2 open to participants now, 2 under way, none of them phase 3. Valganciclovir · Cytomegalovirus Infections.

Enrollment
32nd of 35
6 · median 54
Started
2015
with 2 others
Phase 3
13 of 35
none open now
Registered
26th of 35
by date
Lead sponsor
2 of 35
Chimerix

Among the 35 studies testing valganciclovir in Cytomegalovirus Infections, this one is the 32nd largest by enrollment, is one of 3 that started in 2015, is one of 13 in phase 3, and was the 26th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

2 of the 35 studies testing valganciclovir in Cytomegalovirus Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About valganciclovir

Valganciclovir: first FDA approval 2001 (VALCYTE), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing valganciclovir in Cytomegalovirus Infections, or all of them as a file.
02

Study summary

This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy.

Read the detailed description

This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV-seropositive kidney transplant recipients who received antilymphocyte induction therapy. The study comprised a screening evaluation period (up to 14 days posttransplant), a treatment period (up to 14 weeks posttransplant), and a posttreatment follow-up period (10 weeks, through Week 24 posttransplant).

03

Conditions studied

  • Cytomegalovirus Disease
  • Kidney Transplant Infection

Keywords

  • Cytomegalovirus
  • CMV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must have met all of the following criteria, as applicable, to be eligible to participate in this study:

  1. Were male or female kidney transplant recipients who were ≥18 years of age (subject to local law/practice for clinical trial participation) and ≤14 days following their first or second renal allograft.
  2. Were at high risk of cytomegalovirus (CMV) infection, which for the purposes of this study, was defined as CMV-seropositive recipients who received lymphocyte depleting induction treatment with antithymocyte globulin (Thymoglobulin® or Atgam®) prior to or during the qualifying transplant.
  3. Had an estimated of >10 mL/min ( equation) at screening based on local laboratory results.
  4. Were CMV viremia negative (i.e., "not detected") as measured by the designated central virology laboratory using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test no more than 5 days prior to subject randomization, and at all prior assessments performed since transplant under local standard of care.
  5. Were able to ingest, absorb, and tolerate tablets.
  6. If male, was willing to use an acceptable method(s) throughout the duration of his participation in the study, i.e., through Week 24.
  7. If female of , i.e., not or surgically sterile, was willing to use 2 acceptable contraceptive methods, 1 of which must have been a barrier method, throughout the duration of her participation in the study, i.e., through Week 24.
  8. Were willing and able to provide .
  9. Were willing and able to participate in all required study activities for the entire duration of the study (i.e., through Week 24).

Exclusion criteria

Exclusion Criteria

Subjects who met any of the following criteria were not eligible to participate in this study:

  1. Weighed ≤50 kg (110 lbs) or ≥120 kg (265 lbs).
  2. Were pregnant or breastfeeding or intended to conceive during the study period (i.e., through Week 24).
  3. Received a stem cell transplant or solid organ transplant other than a kidney transplant.
  4. Had suspected CMV disease (either syndrome or tissue-invasive disease) or detectable CMV viremia by the central virology laboratory prior to the first dose of study drug.
  5. Had a history of CMV disease (either syndrome or tissue-invasive disease) within 6 months prior to the first dose of study drug.
  6. Had an of \< 500 cells/μL, count of \< 25,000 platelets/μL, or of \< 8 g/dL at screening.
  7. Had (not including renal dysfunction or an eye disorder) to valganciclovir (vGCV), ganciclovir (GCV), cidofovir (CDV), or brincidofovir (BCV) or their .
  8. Had received (or who are anticipated to need treatment with) any of the following:

    • GCV, vGCV, foscarnet, intravenous CDV, or any other anti-CMV therapy (including CMV immune globulin, cell-based therapies, and anti-CMV drugs, e.g., leflunomide, letermovir [previously AIC246], or maribavir) at any time posttransplant;
    • Any anti-CMV vaccine at any time;
    • Any other investigational drug within 14 days prior to the first dose of study drug (unless prior approval had been received from the Chimerix Medical Monitor or designee); or
    • Prior treatment with BCV at any time. [Note: An "investigational drug" was defined as any drug that was not approved for any indication by the FDA (or appropriate regulatory authority).]
  9. Received acyclovir (ACV) orally at >2000 mg total daily dose (TDD) or intravenously at >15 mg/kg TDD, valacyclovir (vACV) at > 3000 mg TDD on the first dose of study drug or were anticipated to receive any of these drugs at the doses described after the first dose of study drug.
  10. Were infected with , virus (HBV), and/or virus (HCV), had evidence of active viral replication within 6 months prior to screening, as demonstrated by detectable HIV or HCV RNA, or detectable HBV DNA in blood, plasma or serum.
  11. Had severe vomiting, diarrhea or malabsorption syndrome on or prior to the first dose of study drug.
  12. Had gastrointestinal (GI) disease that would have, in the judgment of the investigator, precluded the subject from taking or absorbing oral medication (e.g., gastroparesis, diabetic autonomic neuropathy affecting the GI tract, clinically active Crohn's disease, ischemic colitis, moderate or severe ulcerative colitis, small bowel resection, ileus, or any condition expected to require abdominal surgery during the course of study participation).
  13. Had serum or aspartate aminotransferase concentrations >5 x the (ULN).
  14. Had total serum >2 x the ULN and direct bilirubin >1.5 x the ULN.
  15. Had moderate (Class B) to severe (Class C) hepatic dysfunction according to the Turcotte scoring system.
  16. Received or would require digoxin or ketoconazole therapy (other than topical formulations) during the treatment phase of the study.
  17. Had active (with the exception of basal cell carcinoma).
  18. Had a serious psychiatric, medical disorder, including abnormal laboratory values, that would have, in the judgment of the investigator, put the subject at increased risk by participating in the study, or would have interfered with the conduct of study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
6 participants (actual)

Study arms

  • Active comparator
    Treatment 1

    100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.

    Drug: Brincidofovir

  • Active comparator
    Treatment 2

    900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.

    Drug: Valganciclovir

Interventions

06

What researchers measure

Primary outcomes

  1. The Incidence of Cytomegalovirus (CMV) Disease

    The incidence of CMV disease, which included CMV tissue-invasive disease and CMV syndrome, occurring anytime between randomization and Week 24 posttransplant (±14 days). The proportion of subjects who met this failure endpoint were to be compared between brincidofovir (BCV) and valganciclovir (vGCV) using an unadjusted 95% confidence interval (CI) of the absolute difference between groups (BCV minus vGCV). Number of failures and failure rates were to be presented for each treatment. If the upper bound of the 95% CI fell below 10%, BCV would have demonstrated non-inferiority to vGCV. In the event that the upper bound of the 95% CI fell below 0%, BCV would have additionally demonstrated superiority over vGCV.

    Time frame: 24 weeks (±14 days)

07

Results

Posted Jul 16, 2021
Limitations and caveats
The study was terminated. Enrollment was suspended and all blinded study treatment was discontinued in early January 2016. No conclusions can be made from this study.

Participant flow

Participant flow — Overall Study
MilestoneTreatment 1Treatment 2
Started33
Blinded treatment period12
Completed00
Not completed33
Withdrew: Study terminated33

Outcome measures

PrimaryThe Incidence of Cytomegalovirus (CMV) Disease

The incidence of CMV disease, which included CMV tissue-invasive disease and CMV syndrome, occurring anytime between randomization and Week 24 posttransplant (±14 days). The proportion of subjects who met this failure endpoint were to be compared between brincidofovir (BCV) and valganciclovir (vGCV) using an unadjusted 95% confidence interval (CI) of the absolute difference between groups (BCV minus vGCV). Number of failures and failure rates were to be presented for each treatment. If the upper bound of the 95% CI fell below 10%, BCV would have demonstrated non-inferiority to vGCV. In the event that the upper bound of the 95% CI fell below 0%, BCV would have additionally demonstrated superiority over vGCV.

Time frame:
24 weeks (±14 days)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment 1—0/3 (0%)3/3 (100%)
Treatment 2—0/3 (0%)1/3 (33.3%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTreatment 1Treatment 2
DiarrhoeaGastrointestinal disorders2/30/3
Abdominal discomfortGastrointestinal disorders2/30/3
Alanine aminotransferase increasedInvestigations2/30/3
Muscle spasmsMusculoskeletal and connective tissue disorders1/30/3
Aspartate aminotransferase increasedInvestigations1/30/3
DizzinessNervous system disorders1/30/3
Hot flushVascular disorders1/30/3
Diarrhoea intermittentGastrointestinal disorders1/30/3
FlatulenceGastrointestinal disorders1/30/3
HypophosphataemiaMetabolism and nutrition disorders0/31/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment 1Treatment 2Total
Mean48 (39 to 58)53.7 (48 to 61)50.8 (39 to 61)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment 1Treatment 2Total
Female213
Male123
08

Study locations

3 sites
  • St. Vincent Medical Center
    Los Angeles, California 90057, United States
  • University of Colorado Hospital/Health Science Center
    Aurora, Colorado 80045, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06520, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in May 2016, 8 months.

Results were first posted in Jul 2021, 5 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2015
First posted
May 12, 2015
StartActual
Sep 2015
Primary completionActual
May 15, 2016
CompletionActual
Jul 31, 2016
Results first posted
Jul 16, 2021
Last update
Jul 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02439957
Lead sponsor
Chimerix
Responsible party
Sponsor
First posted
May 12, 2015
Start date
Sep 2015
Primary completion
May 15, 2016
Completion
Jul 31, 2016
Results posted
Jul 16, 2021
Last update
Jul 16, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brincidofovir · Valganciclovir

Start the discussion